There are currently 18 active clinical trials seeking participants for Venous Thromboembolism research studies. The states with the highest number of trials for Autism participants are Ontario, Florida, California and Texas.
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
NCT05966740
Recruiting
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
Gender:
All
Ages:
Between 3 months and 12 years
Trial Updated:
04/01/2024
Locations: University of California, San Diego, La Jolla, California +3 locations
Conditions: Venous Thromboembolism
Register for Updates
Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients
NCT05226793
Recruiting
Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be included. Collected data will be analyzed to determine the safety and effectiveness of the varying enoxaparin doses, and results will be presented at the American Society of Health-System Pharmacists Midyear conference in December 2022.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Methodist Richardson Medical Center, Richardson, Texas
Conditions: Venous Thromboembolism
Register for Updates
Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)
NCT03728166
Recruiting
Hospitalized medical patients have an increased risk of venous thromboembolism (VTE) across the continuum of care, including after hospital discharge. In the APEX Trial of hospitalized patients with acute medical illness, extended-duration post-discharge thromboprophylaxis with oral betrixaban reduced the frequency of asymptomatic proximal deep venous thrombosis (DVT), symptomatic proximal or distal DVT, symptomatic nonfatal pulmonary embolism (PE), or VTE-related death compared with short-durat... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
03/03/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Venous Thromboembolism
Register for Updates
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
NCT04295486
Recruiting
This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.
Gender:
All
Ages:
19 years and above
Trial Updated:
02/28/2024
Locations: University of Miami Hospital, Miami, Florida
Conditions: Venous Thromboembolism
Register for Updates
Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT
NCT04504318
Recruiting
Subcutaneous enoxaparin is currently the gold standard for VTE chemoprophylaxis. However, the efficacy of chemoprophylaxis with subcutaneous enoxaparin is affected by patient-level factors, thus, resulting in VTE events despite guideline-compliant prophylaxis. A population at particular risk is the growing number of patients who undergo autologous breast reconstruction. Direct oral anticoagulants (DOAC) might be a less invasive, yet, more efficacious mode of chemoprophylaxis in this patient popu... Read More
Gender:
Female
Ages:
Between 18 years and 89 years
Trial Updated:
02/14/2024
Locations: Stanford University Medical Center, Stanford, California
Conditions: Venous Thromboembolism
Register for Updates
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
NCT02832245
Recruiting
The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism. The main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (... Read More
Gender:
All
Ages:
All
Trial Updated:
02/12/2024
Locations: Yale University School of Medicine, New Haven, Connecticut +236 locations
Conditions: Venous Thromboembolism
Register for Updates
Examining the Experiences of Children With Blood Disorders
NCT04600609
Recruiting
This is a 3-phase mixed methods study design. A literature review (Phase 1) has been completed to determine the areas of exploration and to identify challenges faced and the impact of the blood disorder on pediatric patients. Based on Phase 1, Phases 2 and 3, as proposed in this study, will be completed and will include interviews of patients diagnosed with bleeding and thrombotic disorders (phase 2). The interviews will be individual, semi-structured, and consist of open-ended questions to elic... Read More
Gender:
All
Ages:
Between 12 years and 21 years
Trial Updated:
01/24/2024
Locations: The University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Blood Disease, Thrombotic Disorder, Venous Thromboembolism, Hemostatic Disorder, Bleeding Disorder
Register for Updates
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT05171075
Recruiting
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +166 locations
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049
Recruiting
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +195 locations
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917
Recruiting
This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of subjects with symptomatic unilateral iliofemoral DVT. The study will collect data on demographics, comorbidities, details from the DVT diagnosis and treatment, and clin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: Honor Health, Scottsdale, Arizona +39 locations
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Register for Updates
PET Fibrin Imaging of DVT and PE
NCT04022915
Recruiting
This study aims to investigate a novel positron emission tomography(PET)-probe for imaging of fresh intravascular blood clots in pulmonary embolism (PE) and deep venous thrombosis (DVT).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
Register for Updates
Supplemental Oxygen in Pulmonary Embolism (SO-PE)
NCT05891886
Recruiting
A study of how supplemental oxygen helps patients with acute pulmonary embolism (PE). Hypothesis: Oxygen affects right ventricular dysfunction (RVD) in patients with acute pulmonary embolism (PE) primarily by relieving hypoxic pulmonary vasoconstriction and reducing pulmonary pressure (PA) pressure, and that this process is metabolically driven.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pulmonary Embolism, Venous Thromboembolism, Metabolomics, Oxygen Inhalation Therapy
Register for Updates